Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes mellitus: how to choose the right solution

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article discusses modern approaches to the treatment of patients with type 2 diabetes mellitus (DM2) using drugs from the group of glucagon-like peptide-1 receptor agonists (GLP-1 argonists). Reasonable recommendations for the use of these drugs are presented; taking into account the modern strategy for the DM2 treatment.

Full Text

Restricted Access

About the authors

M. B. Antsiferov

Endocrinological dispensary of the Moscow Healthcare Department

Email: koala58@mail.ru
ORCID iD: 0000-0002-9944-2997
SPIN-code: 1035-4773
Russian Federation, Moscow

Olga M. Koteshkova

Endocrinological dispensary of the Moscow Healthcare Department

Author for correspondence.
Email: koala58@mail.ru
ORCID iD: 0000-0001-8428-4116
SPIN-code: 6141-1224

Cand. Sci. (Med.) Head of the Department of Education and Treatment of Diabetes

Russian Federation, Moscow

D. M. Antsiferova

Russian Medical Academy of Continuous Professional Education

Email: koala58@mail.ru
ORCID iD: 0000-0002-3920-5914
Russian Federation, Moscow

N. A. Demidov

Shcherbinka City Hospital of the Moscow Healthcare Department

Email: koala58@mail.ru
ORCID iD: 0000-0001-8289-0032
SPIN-code: 7715-4508
Russian Federation, Moscow

References

  1. URL: https://www. diabetesatlas.org. Facts & figures (idf.org); https://www.idf.org/aboutdiabetes/what-is-diabetes/facts-figures.html
  2. Muscelli E.; Mari A.; Casolaro A.; et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes. 2009;57(5):1340–348. doi: 10.2337/db07-1315.
  3. Nauck M.A.; Muller T.D. Incretin hormones and type 2 diabetes. Diabetol. 2023;66:1780–95. doi: 10.1007/s00125-023-05956-x.
  4. Kieffer T.J.; Habener J.F. The glucagon-like peptides. Endocr Rev. 1999;20(6):876–913. doi: 10.1210/edrv.20.6.0385.
  5. Buteau J. GLP-1 signaling and the regulation of pancreatic β-cells mass/function. Avances en Diabetol. 2015;31(3):3–8. doi: 10.1016/S1134-3230(11)70002-3.
  6. Cryer P.E. Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. Endocrinol. 2012;153(3):1039–48. doi: 10.1210/en.2011-1499
  7. Drucker D.J. The cardiovascular biology of glucagon-like peptide-1. Cell Metab. 2016;24(1):15–30. doi: 10.1016/j.cmet.2016.06.009.
  8. Aldiss P.; Davies G.; Woods R.; et al. Browning’ the cardiac and peri-vascular adipose tissues to modulate cardiovascular risk. Int J Cardiol. 2017;228:265–74. doi: 10.1016/j.ijcard.2016.11.074.
  9. Marso S.P.; Bain S.C.; Consoli A.; et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44. doi: 10.1056/NEJMoa1607141.
  10. Wing R.R.; Bolin P.; Brancati F.L.; et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369:145–54. doi: 10.1056/NEJMoa1212914.
  11. Palmer S.C.; Tendal B.; Mustafa R.A.; et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021;372m4573. doi: 10.1136/bmj.m4573.
  12. Jastreboff A.M.; Aronne L.J.; Ahmad N.N.; et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387:205–16. doi: 10.1056/NEJMoa2206038.
  13. Lingvay I.; Sumithran P.; Cohen R.V.; le Roux C.W. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet. 2022;399:394–405. doi: 10.1016/S0140-6736(21)01919-X.
  14. El Sayed N.A.; Aleppo G.; Aroda V.R.; et al. Standards of сare in diabetes-2023. Diab Care. 2023;46(Suppl. 1):S10–8. doi: 10.2337/dc23-S001.
  15. Lalau J.D.; Kajbaf F.; Bennis Y.; et al. Metformin treatment in patients with type 2 diabetes and chronic kidney disease stages 3A; 3B; or 4. Diab Care. 2018;41:547–53. doi: 10.2337/dc17.
  16. Nauck M.A.; Juris J.; MeierJ.J. Are all GLP-1 agonists equal in the treatment of type 2 diabetes? Eur J Endocrinol. 2019;181:R211–34. doi: 10.1530/EJE-19-0566.
  17. Overgaard R.V.; Lindberg S.O.; Thielke D. Impact on HbA1c and body weight of switching from other GLP-1 receptor agonists to semaglutide: A model-based approach. Diab Obes Metab. 2019;21:43–51. doi: 10.1111/dom.13479.
  18. Meier J.J. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012:8:728–42. doi: 10.1038/nrendo.2012.140.20-17.
  19. Drucker D.J.; Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–705. doi: 10.1016/S0140-6736(06)69705-5.
  20. Davies M.J.; Bergenstal R.; Bode B.; et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. J Am Med Associat. 2015;314:687–99. doi: 10.1001/jama.2015.9676.
  21. Frias J.P.; Bonora E.; Nevarez Ruiz L.A.; et al. Efficacy and safety of dulaglutide 3 mg and 4.5 mg vs. dulaglutide 1.5 mg: 52-week results from AWARD-11 (Abstract 357-OR). Diabetes. 2020;69(Suppl. 1). doi: 10.2337/db20-357-OR.
  22. Frias J.P.; Wynne A.G.; Matyjaszek-Matuszek B.; et al. Efficacy and safety of an expanded dulaglutide dose range: a phase 2; placebo-controlled trial in patients with type 2 diabetes using metformin. Diab. Obes. Metab. 2019;21:2048–57. doi: 10.1111/dom.13764.
  23. Blundell J.; Finlayson G.; Axelsen M.; et al. Effects of once-weekly semaglutide on appetite; energy intake; control of eating; food preference and body weight in subjects with obesity. Diab Obes Metab. 2017;19:1242–51. doi: 10.1111/dom.12932.
  24. Kadouh H.; Chedid V.; Halawi H.; et al. GLP-1 analog modulates appetite; taste preference; gut hormones; and regional body fat stores in adults with obesity. J Clin Endocrinol Metab. 2020;105:1552–63. doi: 10.1210/clinem/dgz140.
  25. Bloemendaal L.V.; Veltman D.J.; Ten J.S.; et al. Brain reward-system activation in response to anticipation and consumption of palatable food is altered by glucagon-like peptide-1 receptor activation in humans. Diab Obes Metab. 2015;17:878–86. doi: 10.1111/dom.12506
  26. Pi-Sunyer X.; Astrup A.; Fujioka K.; et al. A randomized; controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373:11–22. doi: 10.1056/NEJMoa1411892.
  27. O’Neil P.M.; Birkenfeld A.L.; McGowan B.; et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised; double-blind; placebo and active controlled; dose-ranging; phase 2 trial. Lancet. 2018; 392:637–49.
  28. Kelly A.S.; Auerbach P.; Barrientos-Perez M.; et al. A randomized; controlled trial of liraglutide for adolescents with obesity. N Engl J Med. 2020;382:2117–28. doi: 10.1056/NEJMoa1916038.
  29. Drucker D.J.; Buse J.B.; Taylor K.; et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised; open-label; non-inferiority study. Lancet. 2008;372:1240–50. doi: 10.1016/S0140-6736(08)61206-4.
  30. Schlogl H.; Kabisch S.; Horstmann A.; et al. Exenatide-induced reduction in energy intake is associated with increase in hypothalamic connectivity. Diab Care. 2013;36:1933–40. doi: 10.2337/dc12-1925
  31. Wadden T.A.; Tronieri J.S.; Sugimoto D.; et al. Liraglutide 3.0 mg and intensive behavioral therapy (IBT) for obesity in primary care: the SCALE IBT randomized controlled trial. Obesity (Silver Spring). 2020;28:529–36. doi: 10.1002/oby.22726.
  32. Pieber T.R.; Bode B.; Mertens A.; et al. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre; open-label; randomised; phase 3a trial. Lancet. Diab Endocrinol. 2019;7:528–39. doi: 10.1016/S2213-8587(19)30194-9.
  33. Miyagawa J.; Odawara M.; Takamura T.; et al. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study. Diab Obes Metab. 2015;17:974–83. doi: 10.1111/dom.12534.
  34. Gerstein H.C.; Colhoun H.M.; Dagenais G.R.; Diaz R. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind; randomised placebo-controlled trial. Lancet. 2019;394(10193):121–30. doi: 10.1016/S0140-6736(19)31149-3.
  35. Abd El Aziz M.; Cahyadi O.; Meier J.J.; et al. Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials. Diab Obes Metab. 2019;22;699–704. doi: 10.1111/dom.13924.
  36. Steinberg W.M.; Buse J.B.; Ghorbani M.L.M.; et al. Amylase; lipase; and acute pancreatitis in people with type 2 diabetes treated with liraglutide: results from the LEADER randomized trial. Diab Care. 2017;40:966–72. doi: 10.2337/dc16-2747.
  37. Marx N.; Federici M.; Schott K.; et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC). Eur Heart J. 2023;00:1–98. doi: 10.1093/eurheartj/ehad192.
  38. Laux G.; Berger S.; Szecsenyi J.; et al. Prescribing differences in family practice for diabetic patients in Germany according to statutory or private health insurance: the case of DPP-4 inhibitors and GLP-1-agonists. BMC. Fam Pract. 2016;17:146. doi: 10.1186/s12875-016-0543-7.
  39. Hong D.; Si L.; Jiang M.; et al. Cost effectiveness of sodium-glucose cotransporter-2 (SGLT2) inhibitors; glucagon-like peptide-1 (GLP-1) receptor agonists; and dipeptidyl peptidase-4 (DPP-4) inhibitors: a systematic review. PharmacoEconom. 2019;37:777e818. doi: 10.1016/j.jval.2019.04.587.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig.1.

Download (173KB)
Indexing metadata
3. Fig.2.

Download (192KB)
Indexing metadata
4. Fig.3.

Download (1MB)
Indexing metadata
5. Fig.4.

Download (73KB)
Indexing metadata
6. Fig.5.

Download (104KB)
Indexing metadata
7. Fig.6.

Download (78KB)
Indexing metadata
8. Fig.7.

Download (66KB)
Indexing metadata
9. Fig.8.

Download (47KB)
Indexing metadata
10. Fig.9.

Download (76KB)
Indexing metadata
11. Fig.10.

Download (76KB)
Indexing metadata

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies